ストックスクリーナーアプリを入手
1.28
50.98%
0.4256
前日終値:
$0.8544
開ける：
$1.08
24時間の取引高:
63.83M
Relative Volume:
56.79
時価総額：
$7.52M
収益：
-
当期純損益:
$-15.52M
株価収益率:
-0.0689
EPS:
-18.58
ネットキャッシュフロー:
$-16.61M
1週間 パフォーマンス:
+35.93%
1か月 パフォーマンス:
+50.00%
6か月 パフォーマンス:
-58.25%
1年 パフォーマンス:
-75.00%
1日の値動き範囲:
$1.02
$1.45
1週間の範囲:
$0.7066
$1.45
52週間の値動き範囲:
$0.702
$4.872
Revelation Biosciences Inc Stock (REVB) Company Profile
名前
Revelation Biosciences Inc
セクター
電話
650-800-3717
住所
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
REVB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
1.27 | 5.06M | 0 | -15.52M | -16.61M | -18.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.84 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.20 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
825.34 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.46 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.86 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Revelation Biosciences Inc (REVB) 最新ニュース
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Decline After 2 Consecutive Days Of Gains—Intel, CSX In Focus (UPDATED) - Benzinga
Revelation Biosciences (REVB) Secures FDA Agreement for Gemini Drug's Clinical Trial Pathway - Intellectia AI
Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours? - Benzinga
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - citizen-times.com
Revelation Biosciences reaches FDA agreement on AKI treatment pathway By Investing.com - Investing.com Nigeria
Revelation Biosciences Reaches FDA Agreement on Gemini for AKI - TradingView — Track All Markets
Targets Report: What is Revelation Biosciences Inc. Equity Warrant’s valuation compared to sectorWeekly Trade Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI - USA Today
Revelation Biosciences reaches FDA agreement on AKI treatment pathway - Investing.com
FDA, Revelation map single trial for deadly kidney injury drug - Stock Titan
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) - delawareonline.com
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development - newportri.com
Will Revelation Biosciences Inc. Equity Warrant benefit from green energy policiesDay Trading Setups & Free Unlock Rapid Growth Potential - bollywoodhelpline.com
Will Revelation Biosciences Inc. Equity Warrant be affected by tariffsDollar Strength & Low Drawdown Investment Ideas - bollywoodhelpline.com
How Revelation Biosciences Inc. stock trades before earningsMarket Trend Report & Stepwise Entry and Exit Trade Signals - bollywoodhelpline.com
Treasury Yields: Is PLYA likely to announce a buybackJuly 2025 Spike Watch & AI Driven Price Forecasts - baoquankhu1.vn
Revelation Biosciences (REVB) to Present Kidney Disease Treatment Data at Conference - Intellectia AI
Revelation Bio To Share New Data From PRIME Study Of Gemini In March - Nasdaq
EPS Watch: Will ZBAI stock recover after earningsGlobal Markets & Weekly High Return Opportunities - baoquankhu1.vn
Breakout Zone: Can Revelation Biosciences Inc lead its sector in growth2025 Market Trends & Fast Moving Stock Trade Plans - baoquankhu1.vn
Whittier Daily News - FinancialContent
New kidney study to show how Gemini may help acute injury patients - Stock Titan
Aug Opening: What risks investors should watch in Revelation Biosciences Inc Equity Warrant stock - Bộ Nội Vụ
Wall Street Recap: Can Revelation Biosciences Inc beat the S P 500Weekly Trade Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Earnings Recap: Will Revelation Biosciences Inc Equity Warrant benefit from green energy policiesEarnings Summary Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Biotech recruits new employee with 90,000 stock units over 2 years - Stock Titan
Revelation Biosciences Inc (REVB) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.08%
大文字化:
|
ボリューム (24 時間):